On March 14, 2025, the Beijing Pharmaceutical Quality Control and Improvement Center (Beijing Pharmaceutical Quality Control Center) convened its 2024 annual pharmaceutical quality control review and 2025 work deployment meeting. The meeting was attended by Deputy Director Yang Yang from the Pharmaceutical and Medical Device Division of the Beijing Municipal Health Commission, Director Zhao Yingbo from the National Pharmaceutical Quality Control Center Office and the Pharmaceutical Management Research Department of the National Institute of Hospital Administration, National Health Commission and Zhai Suodi, Director of the Beijing Pharmaceutical Quality Control Center. Deputy Directors Hu Xin and Yang Yiheng of the Center, as well as the heads of 11 pharmaceutical quality control working groups also attended the event and delivered speeches. More than 600 representatives including heads from district health commissions, the Economic and Technological Development Zone’s administrative bureau, district-level pharmaceutical quality control centers, and various healthcare institutions participated in the meeting.
The conference was chaired by Hu Xin. In his opening remarks, Deputy Director Yang Yang emphasized the importance of directly addressing issues in quality control feedback to ensure effective improvements in pharmaceutical quality management. Director Zhai Suodi then delivered a speech on briefing and outlining the key priorities and significance of future pharmaceutical quality control efforts. From a national perspective, Director Zhao Yingbo from the National Institute of Hospital Administration provided insights into pharmaceutical quality control strategies, analyzing the upcoming core pharmaceutical quality control indicators. His discussion covered various aspects of pharmaceutical quality control, including human resource allocation, pharmaceutical management structures, prescription and medication order reviews, grassroots pharmaceutical coordination mechanisms, controlled drug management, antimicrobial drug use and management, and off-label drug usage. Looking ahead, Director Zhao highlighted the need to strengthen capacity-building at the grassroots level, monitor antimicrobial prescription practices, improve the management of surplus medications, and enhance compliance with intravenous therapy guidelines for inpatients.
Director Yang Yiheng, based on the 2024 key initiatives of the Pharmaceutical Quality Control Center, provided feedback on issues to district-level quality control centers, specialized teams, and medical institutions. The feedback covered antimicrobial classification management, key monitored drugs, compliance with intravenous infusion guidelines, and the training of critical personnel. Looking ahead, the Municipal Pharmaceutical Quality Control Center will enhance data-driven quality control, making full use of the data quality control platform to ensure timely responses, refined management, and strengthened feedback mechanisms. Additionally, through data reporting, standardized operational guidance, and targeted on-site inspections, Director Yang outlined the 2025 work requirements for various medical institutions and district-level quality control centers.
During the meeting, 11 specialized quality control teams—including those focusing on community prescription reviews, secondary and tertiary hospital prescription evaluations, rational medication use and adverse drug reaction monitoring, special rectification of antimicrobial drugs and operation of the monitoring network, mycoplasma resistance surveillance, bacterial resistance monitoring, management of narcotic drugs and Class I psychotropic substances, intravenous medication centralized dispensing and quality management, therapeutic drug monitoring, quality control of obstetric pharmacy and oncology pharmacy—provided detailed assessments of challenges identified in 2024 and presented their current work progress and key work plans for 2025.
Director Zhai Suodi concluded the meeting by reiterating the shared responsibility of improving pharmaceutical services and treatment quality. He expressed confidence that enhancing pharmaceutical quality in parallel with medical quality would foster collaborative innovation and drive the overall advancement of healthcare services.
This conference was not only a comprehensive review of the year's quality control efforts but also a strategic mobilization for advancing pharmaceutical quality during the 14th Five-Year Plan period. As China continues to implement new productive forces in the medical and pharmaceutical fields, the Beijing Pharmaceutical Quality Control Center will further develop intelligent quality control platforms, strengthen interdisciplinary collaboration, and promote standardized, precision-based quality management. These initiatives aim to reinforce rational drug use and solidify Beijing’s position as a leader in high-quality healthcare services.
